Table 4.
Tumour-to-liver density (TLD) at baseline and follow-up (in HU) and difference in TLD (baseline−follow-up) for all patients, unblinded to chemotherapy (FOLFOX and FOLFIRI)
| TLD |
Difference in TLD (mean HU ± SD) | p value | |||
|---|---|---|---|---|---|
| Baseline (mean HU ± SD) | Follow-up (mean HU ± SD) | ||||
| FOLFOX + FOLFIRI | Plain | 15.8 ± 9.0 | 16.3 ± 12.4 | −0.6 ± 13.2 | 0.417 n.s. |
| Arterial | 22.5 ± 11.1 | 23.4 ± 19.5 | 0.9 ± 15.7 | 0.382 n.s. | |
| Portal venous | 40.5 ± 18.2 | 27.8 ± 20.3 | −12.8 ± 19.7 | 0.0008 s. | |
| FOLFOX | Plain | 20.6 ± 7.3 | 19.4 ± 11.0 | −1.3 ± 11.0 | 0.347 n.s. |
| Arterial | 23.5 ± 11.4 | 27.0 ± 19.4 | 3.5 ± 17.3 | 0.232 n.s. | |
| Portal venous | 46.6 ± 17.0 | 34.3 ± 23.5 | −12.3 ± 21.4 | 0.018 s. | |
| FOLFIRI | Plain | 10.9 ± 8.0 | 13.3 ± 11.6 | 2.4 ± 15.4 | 0.299 n.s. |
| Arterial | 21.4 ± 11.2 | 19.7 ± 19.6 | −1.7 ± 14.2 | 0.33 n.s. | |
| Portal venous | 33.1 ± 17.3 | 19.7 ± 12.1 | −13.3 ± 18.2 | 0.01 s. | |
n.s., not significant; s., significant.